ALGS
New deal, new cash
Aligos Therapeutics is doing what every clinical-stage biotech loves to do: turning one asset into real money before the finish line. The company signed an exclusive license agreement with Xiamen Amoytop Biotech for pevifoscorvir sodium, a potential first-in-class HBV therapy, across Greater China.
That territory is no side quest. We’re talking Hong Kong, Macau, Mainland China, and Taiwan — a region with more than 90 million people affected by chronic hepatitis B. Aligos gets a $25 million upfront milestone payment now, plus the chance to collect up to $420 million more tied to clinical, regulatory, and sales milestones, along with tiered royalties on net sales.
Why investors care
This is the biotech version of getting paid twice: first for the partnership itself, then again if the drug actually works. It also lets Aligos keep rights outside Greater China — including the U.S., Europe, Japan, and South Korea — so the company isn’t giving away the whole pizza.
The asset, pevifoscorvir sodium, is already in the Phase II B-SUPREME study, where it’s being compared with tenofovir disoproxil fumarate. The next interim look is expected in the second half of 2026, with final top-line data due in 2027.
Big picture
For a biotech, a deal like this can buy time, credibility, and a much-needed cash cushion without going back to shareholders for more dilution. In other words: less “please fund our science,” more “we found a partner willing to put money on the table.”